Skip to main content

Effectiveness of anticoagulant therapy in the treatment of post-TAVI bioprosthetic thrombosis


Bioprosthetic thromboses are rarely reported in post-transcatheter aortic valve implantation (TAVI). We describe herein the case of bioprosthetic valve thrombosis in an 82-year-old patient which resolved completely after anticoagulant therapy.

Peer Review reports


Aortic valve replacement enables to reduce symptoms and improve morbidity and mortality in patients with severe aortic stenosis [1]. Transcatheter valve replacement represents a safe and well-recognized alternative in inoperable and/or high-operative-risk patients (EuroSCORE, STS) [2-4].

Antithrombotic therapy in the setting of TAVI has been empirically determined, with the most commonly recommended treatment consisting of unfractionated heparin during the procedure followed by dual antiplatelet therapy with aspirin (indefinitely) and clopidogrel (1 to 6 months) [5-7].

To date, there are no referenced cases of described valvular thrombosis in the large prospective cohorts addressing post-TAVI follow-up [8-10]. Other published reports include one case of an Edwards SAPIEN 23 mm valve dysfunction requiring re-operation [11] , one case of early transcatheter aortic valve thrombosis (2 weeks) requiring a second intervention [12]., one case of valve thrombosis which could not be treated by warfarin and requiring surgical intervention [13], one case of prosthesis thrombosis with restricted cusp movement and conserved pressure gradient with complete disappearance 10 weeks after reintroduction of anticoagulant therapy [14], one case of thrombotic aortic stenosis of an Edwards SAPIEN 26 mm valve occurring 4 months after the procedure with total recovery upon vitamin K antagonist (VKA) therapy [15].

Leetma et al. furthermore described 2 cases of refractory heart failure leading to death at respectively day 106 and day 137 following transapical TAVI [16].

Cota et al. also described 3 cases of bioprosthetic dysfunction resulting from valve thrombosis, at respectively 10, 4 and 2 months, all of which were treated with VKA therapy with ad integrum restitution within 2–3 months [17].

Finally, Latib et al. reported 3 cases of SAPIEN XT valve thrombosis assessed during TAVI-follow up, at respectively 6, 15 and 24 months. All three cases were treated with VKA therapy with complete restitution within 1–2 months [18].

Case presentation

We report herein the case of an 82-year-old patient with a respective history of idiopathic thrombocytopenic purpura (ITP), type 2 diabetes, treated dyslipidemia and chronic ischemic heart disease (CD Angioplasty, AIV), recent disabling stroke, Parkinson’s disease, angina pectoris and dyspnea on exertion (NYHA 3). The patient was diagnosed with severe aortic stenosis: annulus = 23 mm, area = 0.85 cm2, minimal aortic insufficiency (AI), transvalvular mean gradient (MG) = 30 mmHg, with consistent LVEF at 55% in transthoracic echocardiography (TTE), pulmonary arterial hypertension (PAH) at 50 mmHg and coronary lesions for which the patient received a stent in the middle segment of the right coronary artery prior to the procedure. EUROSCORE was 26% while STS score was 2.39% risk of mortality and 14.73 % risk of morbidity or mortality.

The patient was implanted with a 26 mm Edwards-Sapien XT Valve via left femoral access without complications.

Echocardiographic control at post-procedure and at one month revealed an aortic valve area of 1.9 cm2, MG = 9 mmHg, with the patient showing clinical improvement.

The patient was re-admitted 5 months after the procedure for syncope and recurrent angina; upon TTE examination: LVEF = 55%, valve area = 0.8 cm2, MG = 56 mmHg.

The non-displaced bioprosthesis presented cusps with reduced mobility in the apical portion, with a predominant obstruction distally to the valve with visible thrombus. Of note, the patient had been under dual anti-platelet therapy (aspirin + clopidogrel) since his discharge.

At this point, the diagnosis of prosthetic valvular thrombosis was evoked.

Upon medico-surgical consensus, it was decided to introduce heparin therapy relayed by VKA treatment (oral anticoagulants).

Upon treatment, the patient quickly improved and at one month after introduction of VKA, TTE showed LVEF = 55%, valve area = 1.8 cm2, Vmax = 1.73 m/s, MG = 15 mmHg, along with disappearance of the thrombosis (Figure 1 A’B’C’)

Figure 1
figure 1

Transesophageal echocardiogram (TEE) of the aortic bioprosthesis in diastole (A) and in systole (B), with transvalvular continuous-wave Doppler (C) revealing a mean gradient (MG) of 64 mmHg and a Vmax of 5 m/s. Same TEE sections and continuous-wave Doppler (A’, B’ and C’) after 1 month of anticoagulant therapy: MG = 15 mmHg and Vmax = 2.7 m/s with unchanged heart rate and ejection fraction.

Three and a half months after introduction of anticoagulant therapy, the patient was controlled with TTE displaying a LVEF = 55%, MG = 10 mmHg with thin cusps showing no thrombosis or obstruction.

For etiological purposes, respective investigation of circulating anticoagulants, anti-B2GP1, anticardiolipids as well as a full thrombophilia work-up were performed and proved negative. A review of clopidogrel resistance by conventional methods was also performed and found to be negative. The only significant anomaly was a thrombocytopenia at 56 G/L in a context of chronic ITP.

Since then, the patient is being treated with long-term aspirin and VKA anticoagulation. Evolution remains uneventful.


We report herein the case of an aortic valve thrombosis after primary percutaneous intervention which was able to be treated through implementation of an anticoagulant (VKA) therapy.

To date, the durability of available bioprosthetic valve devices remains unknown.

Valve thrombosis is a distinct entity defined by the joint recommendations of the AATS/STS/EACTS in order to classify causes of postoperative morbidity and mortality [19].

The incidence of thrombosis of surgically implanted bioprostheses remains low, ranging between 0 and 1% according to the various studies [20-22].

Under the setting of TAVI, one case report described a valve restenosis at 8 months post implantation with large thrombi on 2 of the leaflets without histological evidence of endocarditis, and requiring reoperation while one other case described a 74-year-old patient under corticoid therapy who presented with early valve thrombosis 2 weeks after surgery, and requiring emergency reoperation [12]. In the first case, poor compliance to antiplatelet therapy was described.

In the 2 cases reported by Leetma et al., the diagnosis of stent-valve-thrombosis was assessed by transesophageal echocardiography and multislice computed tomography. This diagnosis was confirmed postmortem by autopsy and histology. Thrombosis occurred shortly after reduction from dual antiplatelet therapy to mono antiplatelet therapy [16].

Cota et al. also described three cases of post-TAVI restenosis under mono antiplatelet therapy at respectively 10, 4 and 2 months follow-up, for which vitamin K antagonist therapy was instituted with restitution of valvular function within 2 to 3 months [17].

In the 3 cases reported by Latib et al. of SAPIEN XT aortic restenosis assessed during TAVI follow-up at respectively 6, 15 and 24 months with recovery after 2 months of VKA treatment, no trigger or changes had been observed to explain this evolution. No thrombus was visible on successive TTE or TEE in these patients [18].

In a review by Mylotte et al., 15 cases of transcatheter heart valve thrombosis occurring 9 ± 7 months after implantation were assessed and found to be successfully treated by prolonged anticoagulation in 75% of the cases [23].

In our patient, in light of the echocardiographic aspect of valve thrombosis, it was decided to initiate anticoagulant therapy which proved to be rapidly effective. This case raises the question of anticoagulant therapy in the aftermath of a TAVI procedure. Such therapy is not recommended outside of specific indications (atrial fibrillation, etc.), with only antiplatelet therapy being recommended.

We also investigated for factors contributing to this valve thrombosis, but were unable to find a causative etiological factor. It would be interesting in the future to collate all cases of early thrombosis of percutaneous valves in order to search for elements possibly favoring such thrombosis.


We report the case of early thrombosis of a percutaneous valve prosthesis effectively treated by oral anticoagulation with excellent outcome.


Written informed consent was obtained from the patient for publication of this Case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.


  1. Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC), European Association for Cardio-Thoracic Surgery (EACTS), Vahanian A, Alfieri O, Andreotti F, Antunes MJ, et al. Guidelines on the management of valvular heart disease (version 2012). Eur Heart J. 2012;33:2451–96.

    Article  Google Scholar 

  2. Vahanian A, Alfieri O, Al-Attar N, Antunes M, Bax J, Cormier B, et al. Transcatheter valve implantation for patients with aortic stenosis: a position statement from the European Association of Cardio-Thoracic Surgery (EACTS) and the European Society of Cardiology (ESC), in collaboration with the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2008;29:1463–70.

    Article  PubMed  Google Scholar 

  3. Hemmann K, Sirotina M, De Rosa S, Ehrlich JR, Fox H, Weber J, et al. The STS score is the strongest predictor of long-term survival following transcatheter aortic valve implantation, whereas access route (transapical versus transfemoral) has no predictive value beyond the periprocedural phase. Interact Cardiovasc Thorac Surg. 2013;17:359–64.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Shahian DM, He X, Jacobs JP, Rankin JS, Welke KF, Filardo G, et al. The Society of Thoracic Surgeons Isolated Aortic Valve Replacement (AVR) Composite Score: a report of the STS Quality Measurement Task Force. Ann Thorac Surg. 2012;94:2166–71.

    Article  PubMed  Google Scholar 

  5. Holmes Jr DR, Mack MJ, Kaul S, Agnihotri A, Alexander KP, Bailey SR, et al. 2012 ACCF/AATS/SCAI/STS expert consensus document on transcatheter aortic valve replacement: developed in collabration with the American Heart Association, American Society of Echocardiography, European Association for Cardio-Thoracic Surgery, Heart Failure Society of America, Mended Hearts, Society of Cardiovascular Anesthesiologists, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance. J Thorac Cardiovasc Surg. 2012;144:e29–84.

    Article  PubMed  Google Scholar 

  6. Rodés-Cabau J, Dauerman HL, Cohen MG, Mehran R, Small EM, Smyth SS, et al. Antithrombotic treatment in transcatheter aortic valve implantation: insights for cerebrovascular and bleeding events. J Am Coll Cardiol. 2013;62:2349–59.

    Article  PubMed  Google Scholar 

  7. Sun JCJ, Davidson MJ, Lamy A, Eikelboom JW. Antithrombotic management of patients with prosthetic heart valves: current evidence and future trends. Lancet. 2009;374:565–76.

    Article  PubMed  Google Scholar 

  8. Hahn RT, Pibarot P, Stewart WJ, Weissman NJ, Gopalakrishnan D, Keane MG, et al. Comparison of transcatheter and surgical aortic valve replacement in severe aortic stenosis: a longitudinal study of echocardiography parameters in cohort A of the PARTNER trial (placement of aortic transcatheter valves). J Am Coll Cardiol. 2013;61:2514–21.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Thomas M, Schymik G, Walther T, Himbert D, Lefèvre T, Treede H, et al. One-year outcomes of cohort 1 in the Edwards SAPIEN Aortic Bioprosthesis European Outcome (SOURCE) registry: the European registry of transcatheter aortic valve implantation using the Edwards SAPIEN valve. Circulation. 2011;124:425–33.

    Article  PubMed  Google Scholar 

  10. Gilard M, Eltchaninoff H, Iung B, Donzeau-Gouge P, Chevreul K, Fajadet J, et al. Registry of transcatheter aortic-valve implantation in high-risk patients. N Engl J Med. 2012;366:1705–15.

    Article  CAS  PubMed  Google Scholar 

  11. Trepels T, Martens S, Doss M, Fichtlscherer S, Schächinger V. Images in cardiovascular medicine: thrombotic restenosis after minimally invasive implantation of aortic valve stent. Circulation. 2009;120:e23–4.

    Article  PubMed  Google Scholar 

  12. Greason KL, Mathew V, Sarano ME, Maleszewski JJ, Suri RM, Rihal CS, et al. Early transcatheter aortic valve thrombosis. J Card Surg. 2013;28:264–6.

    Article  PubMed  Google Scholar 

  13. Pingpoh C, Pache G, Nawras D, Guenkel L, Sami K, Zeh W, et al. Valve thrombosis 7 months after transcatheter aortic valve implantation. Ann Thorac Surg. 2014;98:1079–81.

    Article  PubMed  Google Scholar 

  14. Pache G, Blanke P, Zeh W, Jander N. Cusp thrombosis after transcatheter aortic valve replacement detected by computed tomography and echocardiography. Eur Heart J. 2013;34:3546.

    Article  PubMed  Google Scholar 

  15. Kefer J, Astarci P, Renkin J, Glineur D, Pierard S, Seldrum S, et al. Images and case reports in interventional cardiology: Thrombotic aortic restenosis after transapical Sapien valve implantation. Circ Cardiovasc Interv. 2010;3:289–92.

    Article  PubMed  Google Scholar 

  16. Poulsen SH, Nørgaard BL, Klaaborg KE, Terp K, Høyer S, et al. Two cases of thrombotic stenosis in SAPIEN XT valves after transapical implantation. EuroIntervention J Eur Collab Work Group Interv Cardiol Eur Soc Cardiol. 2014;10(270).

    Google Scholar 

  17. Stabile E, Agrusta M, Sorropago G, Pucciarelli A, Ambrosini V, et al. Bioprostheses ‘thrombosis’ after transcatheter aortic valve replacement. J Am Coll Cardiol. 2013;61:789–91.

    Article  PubMed  Google Scholar 

  18. Latib A, Messika-Zeitoun D, Maisano F, Himbert D, Agricola E, Brochet E, et al. Reversible Edwards Sapien XT dysfunction due to prosthesis thrombosis presenting as early structural deterioration. J Am Coll Cardiol. 2013;61:787–9.

    Article  PubMed  Google Scholar 

  19. Akins CW, Miller DC, Turina MI, Kouchoukos NT, Blackstone EH, Grunkemeier GL, et al. Guidelines for reporting mortality and morbidity after cardiac valve interventions. Ann Thorac Surg. 2008;85:1490–5.

    Article  PubMed  Google Scholar 

  20. Stassano P, Di Tommaso L, Monaco M, Iorio F, Pepino P, Spampinato N, et al. Aortic valve replacement: a prospective randomized evaluation of mechanical versus biological valves in patients ages 55 to 70 years. J Am Coll Cardiol. 2009;54:1862–8.

    Article  PubMed  Google Scholar 

  21. Hammermeister K, Sethi GK, Henderson WG, Grover FL, Oprian C, Rahimtoola SH. Outcomes 15 years after valve replacement with a mechanical versus a bioprosthetic valve: final report of the Veterans Affairs randomized trial. J Am Coll Cardiol. 2000;36:1152–8.

    Article  CAS  PubMed  Google Scholar 

  22. Kodali SK, Williams MR, Smith CR, Svensson LG, Webb JG, Makkar RR, et al. Two-year outcomes after transcatheter or surgical aortic-valve replacement. N Engl J Med. 2012;366:1686–95.

    Article  CAS  PubMed  Google Scholar 

  23. Mylotte D, Andalib A, Thériault-Lauzier P, Dorfmeister M, Girgis M, Alharbi W, et al. Transcatheter heart valve failure: a systematic review. Eur Heart J. 2014. doi:10.1093/eurheartj/ehu388.

Download references


The authors thank Les Services PM-SYS enr. for contribution to the translation and reviewing of the manuscript.

Author information

Authors and Affiliations


Corresponding author

Correspondence to Geraud Souteyrand.

Additional information

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

JD wrote the article, GS is the main correspondent and oversaw the drafting and reading of the article and provided the clinical expertise on the case, PGP conducted the echocardiographic examinations and provided access to the data, PM provided the expertise as well as illustrative layout. All authors have read and approved the manuscript.

Authors’ information

GS, AI and ND are the regional referents for the care management and follow-up of patients undergoing TAVI in Auvergne. GS and ND are interventional cardiologists specializing in this procedure. AI is a cardiovascular surgeon specialized in this procedure.

PM and JRL are university professors and practicing hospital physicians at the University Hospital of Clermont Ferrand and are in charge of the Cardiology pole as a whole including the conducting of TAVI procedures in Auvergne.

PGP is cardiologist/sonographer and oversees the pre-, per- and post-interventional echocardiographic monitoring of these procedures.

Rights and permissions

Open Access  This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.

The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.

To view a copy of this licence, visit

The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Descoux, J., Gautier-Pignonblanc, P., Innorta, A. et al. Effectiveness of anticoagulant therapy in the treatment of post-TAVI bioprosthetic thrombosis. J Cardiothorac Surg 10, 50 (2015).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: